Status:

COMPLETED

Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and Efavirenz

Lead Sponsor:

University Hospital, Geneva

Collaborating Sponsors:

University of Bern

University of Lausanne Hospitals

Conditions:

Sleep Disorders

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Efavirenz causes neuropsychiatric side effects and sleep disturbance, including vivid dreams, dizziness, and abnormal tiredness. These symptoms are frequent during the first weeks of treatment, with s...

Eligibility Criteria

Inclusion

  • Adult patients \> 18 years
  • Signing the study consent form and agree to change ART regimen
  • Stable HAART including EFV since at least 3 months
  • HIV-RNA below 50 copies for at least 3 months

Exclusion

  • No major psychiatric disease (psychosis, severe depression) diagnosed before the initiation of EFV
  • Mentally incompetent patients
  • Pregnancy or lactation Women of childbearing potential must use one or two reliable contraceptive methods during the trial, from day 1 to the end of week 12. Acceptable methods include the birth control pill, IUD, condoms with spermicides. Non-acceptable methods include (non-exhaustive list): Withdrawal, calendar (Onigo method), or spermicides alone.
  • Concomitant renal or hepatic disease:
  • Creatinine above 150 micromol/L
  • Transaminases above 5 times upper normal limit
  • Prothrombin (Quick) value below 50%

Key Trial Info

Start Date :

November 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2009

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT00792584

Start Date

November 1 2008

End Date

June 1 2009

Last Update

September 12 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Geneva Hospital

Geneva, Canton of Geneva, Switzerland, 1211